HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hackett, L. W. Search for Related Content PubMed Articles by Hackett, L. W.

Dried BCG Vaccine

by YOJI OBAYASHI, M.D., Japan Anti-Tubereulosis Association, Tokyo, Japan. 220 pp. WHO Monograph Series No. 28. Columbia Univ. Press, International Documents Service, 2960 Broadway, New York 27, N. Y. 1955. $5.00 (cloth)

The sensitivity of liquid BCG vaccine to light and temperature complicates its use in mass vaccination campaigns against tuberculosis, especially in tropical regions. Freese-drying applied to BCG gives a more stable product but the vaccine loses some of its viability before becoming stabilized. It still retains high antigenic potency for at least a year in the refrigerator but after two years loses a certain amount. There are many compensating advantages over a liquid vaccine, but dried BCG as prepared at present does not fulfill all conditions for practical application on a large scale since it must be kept at below 5°C. This is the chief problem now under investigation.